A look at what the Contemporary Pediatrics® team covered this week.
FDA approves PRIORIX for measles, mumps, and rubella prevention
GSK plc today announced FDA approval of the PRIORIX vaccine for prevention of measles, mumps, and rubella.
Providing gender-affirming care in pediatrics
A conversation on best practices for helping a child who is thinking of transitioning to another gender.
Best practices on discussing birth control for adolescents
Counseling patients about methods of contraception and increasing access to care can help address unplanned pregnancies and sexually transmitted diseases.
Unusual presentation of fever and abdominal pain in a 15-year-old female
An undocumented, Spanish-speaking, 15-year-old female presented to the emergency department with 3 weeks of fever (>101℉) and 3 days of abdominal pain. What's the diagnosis?
Dupilumab May Benefit Skin Barrier Function in Patients with Atopic Dermatitis
Novel Triple-Combination Acne Treatment Shows Early, Significant Results
Top Tips for Optimizing Patient Care
Treating Cannabinoid Hyperemesis Syndrome in the Emergency Department
STDs and Dermatologic Symptoms
Assessing the Prevalence of Medication Errors in Pediatric Care
PRIORIX FDA approval expands supply of MMR vaccines
Dupilumab FDA Approved for AD Patients 6 months to 5 years
Managing genital and pelvic pain in young patients
Infants of vaccinated mothers less likely to test positive for COVID-19
FDA launches “Next Legend” e-cigarette prevention campaign for American indigenous youth
At-risk adolescents with depression less likely to endorse suicidal thoughts on questionnaire
May 6th 2024Investigators sought to evaluate characteristics of adolescents with a history of depression who do not endorse risk via the PHQ item 9, which is commonly used to screen for self-harm and suicide risk.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.